Literature DB >> 9562334

Interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) enhance lipopolysaccharide binding to neutrophils via CD14.

S Takeshita1, K Nakatani, Y Takata, H Kawase, I Sekine, S Yoshioka.   

Abstract

OBJECTIVE: Lipopolysaccharide (LPS), a potent and pleiotropic stimulator of immune cells, binds to neutrophils via CD14, but less densely than to monocytes. The present study was designed to investigate whether cytokines modulate LPS binding to neutrophils via CD14.
METHODS: Neutrophils were cultured with LPS after pretreatment with cytokines, interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 alpha (IL-1alpha), or granulocyte-colony stimulating factor (G-CSF). Binding of LPS and CD14 expression on neutrophils were analyzed by flow cytometry, using anti-LPS and anti-CD14 monoclonal antibodies (mAb).
RESULTS: LPS alone showed only slight binding to neutrophils, but pretreatment with IFN-gamma or TNF-alpha before LPS exposure markedly increased LPS binding and CD14 expression on the surfaces of neutrophils. The dramatic increase in LPS binding was not seen with IL-1alpha or G-CSF. Anti-CD14 blocking mAb completely inhibited the binding effect.
CONCLUSIONS: These results demonstrate that IFN-gamma and TNF-alpha enhance LPS binding to neutrophils via CD14, suggesting that the priming effect of cytokines on neutrophils is important for LPS binding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9562334     DOI: 10.1007/s000110050290

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  9 in total

1.  Increased levels of circulating soluble CD14 in Kawasaki disease.

Authors:  S Takeshita; K Nakatani; H Tsujimoto; Y Kawamura; H Kawase; I Sekine
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Synthesis and surface expression of CD14 by human endothelial cells.

Authors:  H P Jersmann; C S Hii; G L Hodge; A Ferrante
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

3.  Nef protein of human immunodeficiency virus and lipopolysaccharide induce expression of CD14 on human monocytes through differential utilization of interleukin-10.

Authors:  David Creery; Jonathan B Angel; Susan Aucoin; William Weiss; William D Cameron; Francisco Diaz-Mitoma; Ashok Kumar
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

4.  Gamma interferon and lipopolysaccharide interact at the level of transcription to induce tumor necrosis factor alpha expression.

Authors:  J Y Lee; K E Sullivan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Transiently enhanced LPS-induced fever following hyperthermic stress in rabbits.

Authors:  Masaaki Shibata; Tadashi Uno; Walter Riedel; Michiyo Nishimaki; Kaori Watanabe
Journal:  Int J Biometeorol       Date:  2005-06-28       Impact factor: 3.787

6.  Dependence of bacterial protein adhesins on toll-like receptors for proinflammatory cytokine induction.

Authors:  George Hajishengallis; Michael Martin; Hakimuddin T Sojar; Ashu Sharma; Robert E Schifferle; Ernesto DeNardin; Michael W Russell; Robert J Genco
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

7.  Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4.

Authors:  Stephanie K Bunt; Virginia K Clements; Erica M Hanson; Pratima Sinha; Suzanne Ostrand-Rosenberg
Journal:  J Leukoc Biol       Date:  2009-03-04       Impact factor: 4.962

Review 8.  Interferon-gamma activation of polymorphonuclear neutrophil function.

Authors:  Terri N Ellis; Blaine L Beaman
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

9.  IFN-γ and LPS Induce Synergistic Expression of CCL2 in Monocytic Cells via H3K27 Acetylation.

Authors:  Nadeem Akhter; Shihab Kochumon; Amal Hasan; Ajit Wilson; Rasheeba Nizam; Ashraf Al Madhoun; Fatema Al-Rashed; Hossein Arefanian; Fawaz Alzaid; Sardar Sindhu; Fahd Al-Mulla; Rasheed Ahmad
Journal:  J Inflamm Res       Date:  2022-07-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.